User contributions for Alara E. Dagsali
Jump to navigation
Jump to search
30 April 2024
- 18:5818:58, 30 April 2024 diff hist +20 User:AED No edit summary current
- 18:5818:58, 30 April 2024 diff hist +3 Isosulfan Blue No edit summary current
- 18:5718:57, 30 April 2024 diff hist +5,959 N Isosulfan Blue Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |genericName=Lymphazurin |aOrAn=a |indicationType=treatment |indication=Isosulfan blue injection 1% upon subcutaneous administration, delineates lymphatic vessels draining the region of injection. It is an adjunct to lymphography in: primary and secondary lymphedema of the extremities; chyluria, chylous ascites or chylothorax; lymph node involvement by primary or secondary neoplasm; and lymph node response to therape..."
- 18:4718:47, 30 April 2024 diff hist +22 User:AED No edit summary
- 18:4718:47, 30 April 2024 diff hist +3 Ibuprofen Lysine No edit summary current
- 18:4618:46, 30 April 2024 diff hist +15,663 N Ibuprofen Lysine Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |OTC=Yes |genericName=Ibuprofen lysine |aOrAn=a |indicationType=treatment |indication=Ibuprofen Lysine is indicated to close a clinically significant patent ductus arteriosus (PDA) in premature infants weighing between 500 and 1500 g, who are no more than 32 weeks gestational age when usual medical management (e.g., fluid restriction, diuretics, respiratory support, etc.) is ineffective. The clinical trial was conduc..."
- 18:2818:28, 30 April 2024 diff hist +20 User:AED No edit summary
- 18:2818:28, 30 April 2024 diff hist +3 Prussian blue No edit summary current
- 18:2718:27, 30 April 2024 diff hist +14,067 N Prussian blue Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |drugClass=RADIOGARDASE |indicationType=treatment |indication=Radiogardase is indicated for treatment of patients with known or suspected internal contamination with radioactive cesium and/or radioactive or non-radioactive thallium to increase their rates of elimination |adverseReactions=Most common adverse reaction (incidence >24%) was constipation Constipation was reported in 10 (24%) of 42 patients treated with R..."
- 18:1518:15, 30 April 2024 diff hist +23 User:AED No edit summary
- 18:1518:15, 30 April 2024 diff hist +3 Botulism Antitoxin No edit summary current
- 18:1418:14, 30 April 2024 diff hist +18,008 N Botulism Antitoxin Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |genericName=BAT |aOrAn=a |indicationType=treatment |indication=BAT [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] is a mixture of immune globulin fragments indicated for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes A, B, C, D, E, F, or G in adults and pediatric patients. |adverseReactions=The most common adverse reactions obse..."
29 April 2024
- 15:2615:26, 29 April 2024 diff hist +27 User:AED No edit summary
- 15:2515:25, 29 April 2024 diff hist −35 Trastuzumab emtansine No edit summary current
- 15:2315:23, 29 April 2024 diff hist +40,610 N Trastuzumab emtansine Created page with "{{DrugProjectFormSinglePage |authorTag=AlaraE.Dagsali |genericName=ado-trastuzumab emtansine |indicationType=treatment |indication=the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: received prior therapy for metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapy. the adjuvant treatment..."
25 April 2024
- 22:5322:53, 25 April 2024 diff hist −3 Reni Syndrome No edit summary current
- 22:5222:52, 25 April 2024 diff hist −144 User:AED No edit summary
- 22:5122:51, 25 April 2024 diff hist +407 User:AED No edit summary
- 22:4822:48, 25 April 2024 diff hist +3 Adagrasib No edit summary current
- 22:4822:48, 25 April 2024 diff hist +20 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC) No edit summary current
- 22:4522:45, 25 April 2024 diff hist +3 Norelgestromin No edit summary current
- 22:4522:45, 25 April 2024 diff hist +11 Tranexamic No edit summary current
- 22:4422:44, 25 April 2024 diff hist −11 Tranexamic No edit summary
- 22:4122:41, 25 April 2024 diff hist +2 Tranexamic No edit summary
- 22:4122:41, 25 April 2024 diff hist −1 Tranexamic No edit summary
- 22:4022:40, 25 April 2024 diff hist +14 Tranexamic No edit summary Tag: Manual revert
- 22:3922:39, 25 April 2024 diff hist −14 Tranexamic No edit summary Tag: Manual revert
- 22:3922:39, 25 April 2024 diff hist +2,941 N User:AED Created page with "==Alara Ece Dagsali== '''Alara Ece Dagsali''' <br>'''Contact:''' email: alaraecedagsai99@gmail.com; +905313614710 ==Medical Education== *School of Medicine (M.D.): Istanbul Medipol University 2021- 2024 Demiroglu Bilim University 2018-2021 ==Pages authored/Co-authored/Collaborated== ===2023=== ====Authored:==== *Reni Syndrome ==Work Experience== *Wikidoc - Associate Editor-In-Chief, 2023 - Current *Yeditepe University Hospitals Cardiac Electrophysiology Lab, Ista..."
- 22:3622:36, 25 April 2024 diff hist +40 Alara E. Dagsali No edit summary current
24 April 2024
- 21:2621:26, 24 April 2024 diff hist +14 Tranexamic No edit summary Tag: Manual revert
- 21:2621:26, 24 April 2024 diff hist −11 Tranexamic No edit summary
- 21:2521:25, 24 April 2024 diff hist −14 Template:AlaraE.Dagsali No edit summary current
- 21:2521:25, 24 April 2024 diff hist −2 Tranexamic No edit summary Tag: Manual revert
- 21:2321:23, 24 April 2024 diff hist −1 Tranexamic No edit summary
- 21:2321:23, 24 April 2024 diff hist +3 Tranexamic No edit summary Tag: Visual edit: Switched
- 21:2221:22, 24 April 2024 diff hist −1 Tranexamic No edit summary
- 21:2121:21, 24 April 2024 diff hist +88 N Template:AlaraE.Dagsali Created page with " Alara Ece Dagsali, M.D.[mailto:alaraecedagsali99@gmail.com]"
- 21:1421:14, 24 April 2024 diff hist +23,020 N Tranexamic Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |genericName=Tranexamic |aOrAn=a |drugClass=hemophilia drug |indicationType=prevention |indication=Tranexamic acid injection is indicated in patients with hemophilia for short-term use (2 to 8 days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction. |adverseReactions=Thromboembolic Risk Seizures Hypersensitivity Reactions Visual Disturbances Dizzines..."
22 April 2024
- 18:4418:44, 22 April 2024 diff hist 0 N File:D2f97c72-bbfb-426e-b742-6e25234ba1ff 2.jpg No edit summary current
- 18:4318:43, 22 April 2024 diff hist 0 N File:Ae8d4ea7-c895-403b-a435-56dc4996a3b0.JPG No edit summary current
21 March 2024
- 16:5516:55, 21 March 2024 diff hist +43 Norelgestromin No edit summary
- 16:5316:53, 21 March 2024 diff hist +12,388 Norelgestromin No edit summary
- 16:2816:28, 21 March 2024 diff hist +22,456 Norelgestromin No edit summary
- 08:4608:46, 21 March 2024 diff hist +1,580 Norelgestromin No edit summary
- 08:3508:35, 21 March 2024 diff hist +929 Norelgestromin No edit summary
- 08:3308:33, 21 March 2024 diff hist +3,183 N Norelgestromin Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |OTC=Yes |genericName=NORELGESTROMIN AND ETHINLY ESTRADIOL patch |indicationType=prevention |indication=Norelgestromin and ethinyl estradiol transdermal system is indicated for the prevention of pregnancy in women with a body mass index (BMI) < 30 kg/m for whom a combined hormonal contraceptive is appropriate. |hasBlackBoxWarning=Yes |adverseReactions=The following serious adverse reactions with the use of co..."
15 February 2024
- 02:0902:09, 15 February 2024 diff hist +1,330 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC) No edit summary
- 02:0102:01, 15 February 2024 diff hist 0 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC) No edit summary
- 02:0002:00, 15 February 2024 diff hist −40,428 Coronary heart disease in Diabetics Replaced content with "__NOTOC__ {{ADA guidelines}} {{CMG}} {{AE}} {{SCh}}; {{MehdiP}}; {{TarekNafee}} ==2016 ADA Standards of Medical Care in Diabetes Guidelines<ref name="urlcare.diabetesjournals.org">{{cite web |url=http://care.diabetesjournals.org/content/suppl/2015/12/21/39.Supplement_1.DC2/2016-Standards-of-Care.pdf |title=care.diabetesjournals.org |format= |work= |accessdate=}}</ref>== ===Screening=== {|class="wikitable" | bgcolor="Seashell"|<nowiki>"</nowiki>'''1.'''In asymptomatic..." current Tag: Replaced
- 02:0002:00, 15 February 2024 diff hist +40,625 N 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC) Created page with "{{ADA guidelines}} {{CMG}} {{AE}} {{SCh}}; {{MehdiP}}; {{TarekNafee}} ==2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC)<ref name="pmid37622663">{{cite journal| author=Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ | display-authors=etal| title=2023 ESC Guidelines f..."
- 01:5501:55, 15 February 2024 diff hist +1,959 Coronary heart disease in Diabetics No edit summary
- 01:5301:53, 15 February 2024 diff hist +958 Coronary heart disease in Diabetics No edit summary
- 01:4801:48, 15 February 2024 diff hist +5,725 Coronary heart disease in Diabetics No edit summary
- 01:3801:38, 15 February 2024 diff hist +2 Coronary heart disease in Diabetics No edit summary
- 01:3301:33, 15 February 2024 diff hist 0 Coronary heart disease in Diabetics No edit summary
- 01:3201:32, 15 February 2024 diff hist −4 Coronary heart disease in Diabetics No edit summary
- 01:1601:16, 15 February 2024 diff hist +1 Coronary heart disease in Diabetics No edit summary
- 01:1401:14, 15 February 2024 diff hist +3,056 Coronary heart disease in Diabetics No edit summary
- 01:0701:07, 15 February 2024 diff hist −45 Coronary heart disease in Diabetics No edit summary
- 01:0401:04, 15 February 2024 diff hist +2,663 Coronary heart disease in Diabetics No edit summary
- 00:1700:17, 15 February 2024 diff hist +6,524 Coronary heart disease in Diabetics No edit summary
- 00:0500:05, 15 February 2024 diff hist 0 Coronary heart disease in Diabetics →Recommendations for nutrition in patients with type 2 diabetes with or without cardiovascular disease (DO NOT EDIT)== Tag: Visual edit
- 00:0400:04, 15 February 2024 diff hist +1,869 Coronary heart disease in Diabetics No edit summary Tag: Visual edit: Switched
31 January 2024
- 20:3020:30, 31 January 2024 diff hist +28,883 N Adagrasib Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E. Dagsali |genericName=adagrasib |aOrAn=an |indicationType=treatment |indication=KRAZATI is indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test [see DOSAGE AND ADMINISTRATION (2.1)], who have received at least one prior systemic therapy. This indication is approved under accelerated approval based on ob..."
21 December 2023
- 08:4608:46, 21 December 2023 diff hist +4,642 Coronary heart disease in Diabetics No edit summary
- 07:3407:34, 21 December 2023 diff hist +2,774 Coronary heart disease in Diabetics No edit summary
- 07:2007:20, 21 December 2023 diff hist +1 Coronary heart disease in Diabetics /* Recommendations for assessing cardiovascular risk in patients with type 2 diabetes(DO NOT EDIT){{cite journal| author=Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ | display-authors=etal| title=2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. | journal=Eur Heart J | year= 2023 | volume= 44 | issue= 39 | pages= 4043-4140 | pmid=37622663 | doi=10.1093/eurheartj/ehad192 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/el...
- 07:2007:20, 21 December 2023 diff hist +1 Coronary heart disease in Diabetics /* Recommendations for diagnosing diabetes(DO NOT EDIT){{cite journal| author=Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ | display-authors=etal| title=2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. | journal=Eur Heart J | year= 2023 | volume= 44 | issue= 39 | pages= 4043-4140 | pmid=37622663 | doi=10.1093/eurheartj/ehad192 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/c...
- 07:1907:19, 21 December 2023 diff hist +40 Coronary heart disease in Diabetics /* 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes{{cite journal| author=Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ | display-authors=etal| title=2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. | journal=Eur Heart J | year= 2023 | volume= 44 | issue= 39 | pages= 4043-4140 | pmid=37622663 | doi=10.1093/eurheartj/ehad192 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.f...
- 07:1807:18, 21 December 2023 diff hist +503 Coronary heart disease in Diabetics /* Recommendations for assessing cardiovascular risk in patients with type 2 diabetes{{cite journal| author=Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ | display-authors=etal| title=2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. | journal=Eur Heart J | year= 2023 | volume= 44 | issue= 39 | pages= 4043-4140 | pmid=37622663 | doi=10.1093/eurheartj/ehad192 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfr...
- 07:1607:16, 21 December 2023 diff hist +1,572 Coronary heart disease in Diabetics /* Recommendations for assessing cardiovascular risk in patients with type 2 diabetes{{cite journal| author=Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ | display-authors=etal| title=2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. | journal=Eur Heart J | year= 2023 | volume= 44 | issue= 39 | pages= 4043-4140 | pmid=37622663 | doi=10.1093/eurheartj/ehad192 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfr...
- 07:1207:12, 21 December 2023 diff hist +2,107 Coronary heart disease in Diabetics /* 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes{{cite journal| author=Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ | display-authors=etal| title=2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. | journal=Eur Heart J | year= 2023 | volume= 44 | issue= 39 | pages= 4043-4140 | pmid=37622663 | doi=10.1093/eurheartj/ehad192 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.f...
- 07:0207:02, 21 December 2023 diff hist +200 Coronary heart disease in Diabetics No edit summary
- 06:5106:51, 21 December 2023 diff hist +609 Coronary heart disease in Diabetics /* 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes{{cite journal| author=Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ | display-authors=etal| title=2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. | journal=Eur Heart J | year= 2023 | volume= 44 | issue= 39 | pages= 4043-4140 | pmid=37622663 | doi=10.1093/eurheartj/ehad192 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.f...
- 06:4906:49, 21 December 2023 diff hist +1,670 Coronary heart disease in Diabetics /* 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes{{cite journal| author=Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ | display-authors=etal| title=2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. | journal=Eur Heart J | year= 2023 | volume= 44 | issue= 39 | pages= 4043-4140 | pmid=37622663 | doi=10.1093/eurheartj/ehad192 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.f...
- 06:3406:34, 21 December 2023 diff hist +2,943 Coronary heart disease in Diabetics No edit summary
- 06:2306:23, 21 December 2023 diff hist +615 Coronary heart disease in Diabetics No edit summary
23 November 2023
- 15:0015:00, 23 November 2023 diff hist +252 Reni Syndrome No edit summary
- 14:4914:49, 23 November 2023 diff hist +30 Reni Syndrome No edit summary
- 14:4814:48, 23 November 2023 diff hist +541 Reni Syndrome →Treatment
- 14:4714:47, 23 November 2023 diff hist −50 Reni Syndrome →Natural History, Complications and Prognosis
- 14:4614:46, 23 November 2023 diff hist +2,996 Reni Syndrome No edit summary
- 14:0914:09, 23 November 2023 diff hist +376 Reni Syndrome →Differential Diagnosis
- 14:0414:04, 23 November 2023 diff hist +12 Reni Syndrome →Pathophysiology
- 14:0414:04, 23 November 2023 diff hist +4 Reni Syndrome →Overview
- 14:0314:03, 23 November 2023 diff hist +13 Reni Syndrome No edit summary
- 14:0014:00, 23 November 2023 diff hist +1 Reni Syndrome No edit summary
- 13:5913:59, 23 November 2023 diff hist +8,083 Reni Syndrome No edit summary
- 11:2111:21, 23 November 2023 diff hist +499 Reni Syndrome →Historical Perspective
- 11:2111:21, 23 November 2023 diff hist +121 Reni Syndrome →Historical Perspective
22 November 2023
- 23:0723:07, 22 November 2023 diff hist +1,019 Reni Syndrome No edit summary
- 22:5122:51, 22 November 2023 diff hist +341 Reni Syndrome No edit summary
- 22:1122:11, 22 November 2023 diff hist +525 Reni Syndrome No edit summary
- 21:3221:32, 22 November 2023 diff hist −32 Reni Syndrome No edit summary
- 21:3021:30, 22 November 2023 diff hist +5 Alara E. Dagsali →Alara Ece Dagsali
- 21:3021:30, 22 November 2023 diff hist +2,941 N Alara E. Dagsali Created page with "==Alara Ece Dagsali== '''Alara Ece Dagsali''' <br>'''Contact:''' email: alaraecedagsai99@gmail.com; +905313614710 ==Medical Education== *School of Medicine (M.D.): Istanbul Medipol University 2021- 2024 Demiroglu Bilim University 2018-2021 ==Pages authored/Co-authored/Collaborated== ===2023=== ====Authored:==== *Reni Syndrome ==Work Experience== *Wikidoc - Associate Editor-In-Chief, 2023 - Current *Yeditepe University Hospitals Cardiac Electrophysiology Lab, Ista..."
1 November 2023
- 10:4310:43, 1 November 2023 diff hist +1,567 Reni Syndrome →Pathophysiology
- 10:4210:42, 1 November 2023 diff hist +1,566 Reni Syndrome →Historical Perspective
- 10:3410:34, 1 November 2023 diff hist +260 Reni Syndrome No edit summary
- 08:4708:47, 1 November 2023 diff hist +3 Reni Syndrome →OVERVIEW Tag: Visual edit
23 October 2023
- 16:2816:28, 23 October 2023 diff hist +137 Reni Syndrome No edit summary Tag: Visual edit
- 16:1816:18, 23 October 2023 diff hist +2,103 Reni Syndrome No edit summary
- 14:5414:54, 23 October 2023 diff hist +142 N Reni Syndrome RENI syndrome (RENI) is a genetic condition characterized by steroid-resistant nephrotic syndrome and a range of multisystemic manifestations.